ISBN-13: 9786209259630 / Angielski / Miękka / 136 str.
This book explores the emerging field of engineered exosome-antibody conjugates as an innovative platform for overcoming the long-standing challenge of limited drug delivery across the blood-brain barrier. It examines how surface-modification strategies-such as ligand functionalization, membrane engineering, targeted antibodies, and nanoscale optimization-can enhance cellular uptake and improve neurological specificity. The text highlights recent advances in exosome biogenesis control, loading technologies, and conjugation chemistries that increase therapeutic precision while minimizing off-target effects. Special attention is given to translational pathways, including preclinical validation, pharmacokinetic profiling, safety requirements, and regulatory considerations for moving these hybrid biotherapeutics toward clinical application. The book positions exosome-antibody systems as a promising next-generation solution for treating complex brain disorders with higher efficiency and reduced systemic toxicity.